Seres Therapeutics, SER-428, Live Biotherapeutics, Bloodstream Infections, Sepsis, Antibiotic Resistance, Gastrointestinal Microbiome, Enterococcus faecium, Klebsiella pneumoniae,

CAMBRIDGE, Mass., October 15, 2026 Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that preclinical data supporting the development of SER-428,...